View all veterinary jobs
The National Office of Animal Health (NOAH) and the International Federation for Animal Health Europe (IFAH) have welcomed the European Commission's publication of proposals for revised legislation concerning veterinary medicines and medicated feed earlier today.
The EC says the proposals are designed to increase the availability of veterinary medicines, reduce administrative burden, stimulate competitiveness and innovation, improve the functioning of the internal market and address the issue of antimicrobial resistance.
NOAH says that currently, the manufacturers of veterinary medicines struggle with a regulatory system with some serious flaws, including:
NOAH chief executive Phil Sketchley said: "NOAH will be looking at the detail of the texts in the coming days and weeks, and reviewing their potential impact. We look forward to working with the VMD, who have called stakeholder workshops to examine the texts. We will also be supporting our European federation IFAH-Europe as they work determinedly with the European institutions over the coming years to support the Commission's vision for a more efficient regulatory system for veterinary medicines in Europe.
"We believe the value our industry brings to society is very high, despite being quite a small sector. For example, veterinary medicines benefit public health by preventing zoonotic disease and supporting food security.
"With synergies with our own UK Government's commitment to reduce unnecessary red tape, which is a key theme for DEFRA, the animal health industry in Europe needs greater efficiency to cut the red tape for our industry. We look forward to a streamlined registration process which delivers a single European marketing authorisation for all veterinary medicines.
"We will also be considering if the text has any particular implications for the UK animal health market and access to medicines for our animals."
NOAH says it also welcomes the revised medicated feed legislation. Phil Sketchley said: "NOAH believes this is an important route for administering prescription medicines to animals. We will work to help ensure the legislation is capable of maintaining and strengthening this route."
The British Veterinary Association has welcomed the European Commission's Action Plan on Antimicrobial resistance (AMR), launched yesterday on the eve of European Antibiotic Awareness Day.
The Action Plan sets out 12 actions:
However, the association has expressed concern that the Commission has given only qualified support for new antimicrobials for veterinary use. Carl Padgett, President of the BVA, said: "There is much to be applauded in this action plan. In particular the BVA supports the calls for more and better coordinated research, more responsible use of antimicrobials in human and veterinary medicine, and the development of diagnostic tools to quickly and accurately identify the right drug for the right bug.
"The use of antimicrobials in the treatment and control of animal diseases is essential and the BVA supports the strong messages in this plan. Any option for managing AMR must be firmly rooted in sound scientific assessment of the risk.
"While the report recognises the difficulties that have led to the hampering of research into new antimicrobials for veterinary use, we are concerned that there is only qualified support from the Commission for the development of these new medicines for animal use.
"Research into new antimicrobials should be supported in both human and veterinary medicine. We need to ensure the creation of a more predictable regulatory environment to encourage new products for animals to be brought to the market.
"Finally, while the BVA supports the need for a new regulatory framework any new regulations must not impede the ability of veterinary surgeons to prescribe and dispense medicines according to their clinical judgement."
Meanwhile, Jill Moss of the Bella Moss Foundation added her voice to those calling for responsible use of antibiotics, highlighting recent research from the Royal Veterinary College that has established a clear link between pets with MRSA infection and human hospital-associated MRSA. What is less widely recognised, she says, is that resistant bacteria can be passed from human to animal.
The charity is now calling on health and veterinary professionals to work together to achieve a reduction in resistant infections by raising awareness and promoting the responsible use of antibiotics.
The European Commission has agreed with the BSAVA and BVA that controls must be maintained to keep the UK free from the tapeworm Echinococcus multilocularis, and adopted a regulation that will permit pre-movement treatment for dogs travelling to listed Member States (i.e. the UK, Ireland, Finland and Malta).
In June Defra announced that the UK's derogation from European pet travel rules, which allows additional protection for the UK against rabies, ticks and tapeworms, would end on 31 December 2011. The movement rules on rabies and ticks will now be harmonised with the rest of Europe.
However, due to the significant public health risk posed by Echinococcus multilocularis, the BVA and BSAVA (working with Defra, the Federation of Veterinarians of Europe [FVE] and colleagues in Veterinary Ireland) continued to lobby the European Commission for controls on tapeworms to be maintained.
The regulation will ensure that a dog must be treated by a veterinary surgeon 24 to 120 hours (1-5 days) before entering one of the listed countries.
The BVA and BSAVA say they made a scientific case for a treatment window of 24-48 hours, but accept that the Commission had to find a compromise that would assist pet owners travelling during national holidays.
Harvey Locke, President of the BVA said: "This has been a long process but the BVA and BSAVA put forward the strong scientific case for the UK to maintain tapeworm controls and we are delighted that the European Commission has adopted this resolution.
"In our role as guardians of public health, vets were deeply concerned that the removal of tapeworm controls would see the introduction of EM to the UK and Ireland.
"Although relatively benign in dogs, the resulting disease in humans - alveolar echinococcosis - is an invasive, cancer-like cystic stage of the parasite, and is invariably fatal if not treated.
"The next stage of our lobbying will be to ensure that Member States and MEPs from across Europe support the UK's case for the additional controls."
Andrew Ash, President of BSAVA said: "Echinococcus multilocularis is a significant public health threat and we have worked hard to ensure the European Commission understands the potential impact of allowing this zoonotic disease to enter our country.
"The BVA and BSAVA will continue to promote the best possible health and welfare advice for pet owners taking their animals abroad. Our advice to owners is to speak to a vet as early as possible to make sure pets are protected from all diseases and parasites encountered abroad."
The European Commission has published an amendment to Regulation concerning the transitional period under which the UK keeps it's requirements for blood testing, a six month wating period, tick and tapeworm treatment.
The amendment extends the transition period to the 30th June 2010, which means that the current rules applying to pets entering the UK will remain in place until 1st July 2010.